Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

KetoCytonyx reports positive Phase I study of neuroprotectant

BTG : 29 September, 2006  (Technical Article)
Ketocytonyx, Inc., a pharmaceutical development company focused on cell protection therapeutics, today announced the successful completion of a Phase I clinical study of KTX 0101, its lead therapeutic targeting prevention of cognitive impairment in patients undergoing coronary artery bypass graft surgery.
Ketocytonyx, Inc., a pharmaceutical development company focused on cell protection therapeutics, today announced the successful completion of a Phase I clinical study of KTX 0101, its lead therapeutic targeting prevention of cognitive impairment in patients undergoing coronary artery bypass graft surgery.

Twenty healthy volunteers were enrolled into this dose-escalation study. KTX 0101 was found to be well tolerated by all volunteers with no serious adverse events reported. Drug pharmacokinetics were as predicted.

In addition, statistically significant changes, compared to placebo, seen in the electroencephalogram recording indicated that KTX 0101 had a pharmacodynamic effect on the central nervous system. This effect is similar to that seen in patients when hypothermia was used to provide neuroprotection for patients undergoing CABG surgery and following head injury. Hypothermia has been reported to improve functional outcome following traumatic brain injury.

Dr Keith Martin, President of KetoCytonyx, commented: “We are very pleased with the results of our first clinical study, which show that KTX 0101 was very well tolerated at all dose levels. The effect on the EEG recorded from the central nervous system also provides the first data in man to suggest a potential neuroprotectant effect. We are now planning the further clinical development of KTX 0101 to confirm safety and proof of principle as a neuroprotectant in Phase I b and Phase II studies.”

Prof Stanton Newman, Member of the KetoCytonyx Scientific Advisory Board, added: “The demonstration that the infusion of KTX 0101 has a significant effect on the EEG suggests that KetoCytonyx approach to neuroprotection for patients undergoing coronary artery bypass surgery holds great promise”.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 NewMaterials.com
Netgains Logo